Fig. 6.

Blockade of CD49a inhibits CD8⁺ T cell infiltration and the activity of cancer vaccine on head and neck tumors. Mice were grafted with TC1 cells in the tongue and then immunized two times with STxB-E7 mixed with αGalCer (days 5 and 10). (A to C) They were also treated with either anti-CD49a (250 μg, intraperitoneally) or anti-CD103 (150 μg, intraperitoneally) or isotype-matched control mAb at days 8, 11, and 14. CD8⁺ T cell infiltration was detected by immunoenzymatic staining (A), and tumor volume was monitored by MRI at day 20 (B). Kaplan-Meier survival curve of mice bearing a head and neck tumor and treated or not with an intranasal cancer vaccine combined or not with anti-CD49a mAb, anti-CD103 (C), or isotype-matched control. Each experiment included five to six mice per group and was reproduced three times. *P < 0.05, **P < 0.01, ***P < 0.001.